MedTrace Logo

Surveillance of Humira in Korean JIA Patients

NCT02141984 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2017-06-23

Study results available
· View outcomes & findings →

Summary

Approximately 600 pediatric patients prescribed Humira Injection in usual practice according to the approved Korean product label will be registered into this observational study. Baseline data will be obtained at enrollment including demographics, underlying diseases and complications especially in regard to purified protein derivative (PPD) skin test, and chest X-ray. At routine visits for Humira Injection administration, which will occur according to usual medical practice, concomitant medication information and adverse events information will be collected for up to 70 days after the last administration of Humira.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Eunjung Gu, MS · AbbVie korea

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02141984 on ClinicalTrials.gov